Novartis AG (SIX: NOVN; NYSE: NVS) has reported a pivotal Phase III failure for pelacarsen, its experimental cardiovascular drug licensed from Ionis Pharmaceuticals, after lowering lipoprotein(a) failed to translate into fewer major cardiovascular events in an 8,323-patient outcomes trial.
The Lp(a)HORIZON study did not meet its primary endpoint, a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke and urgent coronary revascularisation requiring hospitalisation. The result is striking because pelacarsen did achieve lower Lp(a) levels, separating success against the biological target from success against the clinical outcome that ultimately matters to regulators, physicians and patients.
The trial enrolled patients with established cardiovascular disease and elevated Lp(a), with participants already receiving guideline-directed therapies including lipid-lowering and antihypertensive treatment. Novartis said full data will be presented at a future medical congress, leaving important unanswered questions around the magnitude of Lp(a) reduction, subgroup outcomes, treatment adherence and whether any patient population appeared to derive clinical benefit.
The consequences reach beyond Novartis. Approximately one in five people worldwide are estimated to have elevated Lp(a), which is largely genetically determined and has been associated with cardiovascular risk. Multiple pharmaceutical companies have been developing therapies targeting the pathway, meaning Lp(a)HORIZON was effectively testing not only pelacarsen but a central assumption behind a potentially large new drug category.
Why is lowering Lp(a) without reducing cardiovascular events such an important result?
Drug development frequently uses biomarkers to identify whether a treatment is affecting its intended biological target.
The more difficult question is whether changing that biomarker produces a meaningful clinical benefit.
Pelacarsen is an antisense oligonucleotide designed to inhibit production of apolipoprotein(a), thereby reducing Lp(a). Earlier studies had shown substantial Lp(a) reductions, helping establish the rationale for a large outcomes trial.
Lp(a)HORIZON was designed to answer the harder question: whether those reductions actually prevent events such as heart attacks, strokes and cardiovascular deaths in people who already have cardiovascular disease.
The topline result says that, in the overall trial population and under the study’s design, the answer was not demonstrated.
That does not establish that Lp(a) itself is irrelevant to cardiovascular disease. Nor does it automatically prove that every competing Lp(a)-lowering drug will fail. Different technologies may reduce Lp(a) more deeply, maintain suppression differently or be tested in different patient populations.
It does, however, raise the evidence bar substantially.
Competitors can no longer rely simply on the argument that reducing an established cardiovascular risk biomarker will necessarily translate into fewer events. Outcomes data have become even more important.
How much commercial value was tied to pelacarsen for Novartis and Ionis Pharmaceuticals?
Ionis Pharmaceuticals originally developed pelacarsen and entered a collaboration with Novartis in 2017. Novartis exercised its licensing option in 2019 for $150 million and assumed responsibility for worldwide development and commercialisation.
Under the agreement, Ionis had been eligible for up to $675 million in regulatory and sales milestones connected with pelacarsen, alongside tiered royalties ranging from the mid-teens to low-20% range on potential net sales.
Those economics illustrate why a late-stage failure matters disproportionately to Ionis even though Novartis funds development.
A successful global cardiovascular drug could have created milestone payments and a long-duration royalty stream without Ionis carrying the full commercial infrastructure required to sell it worldwide. Failure at the pivotal outcomes stage weakens that prospective value substantially unless deeper analysis identifies a viable regulatory or development path.
For Novartis, pelacarsen was one of several important pipeline assets intended to support growth as established products face competitive and patent pressure. Reuters reported that pelacarsen, remibrutinib and del-desiran had collectively been viewed as potential products capable of more than $10 billion in peak annual sales if successful, although that figure spans three programmes rather than pelacarsen alone.
That context helps explain why the result attracted immediate investor attention.
Does the failure threaten every company developing an Lp(a)-lowering drug?
Not necessarily, but it changes the discussion.
Companies including Eli Lilly and Amgen are pursuing different technologies intended to reduce Lp(a), and some programmes may produce deeper or more sustained reductions than pelacarsen.
What Lp(a)HORIZON challenges is the simplest version of the investment thesis: that genetically elevated Lp(a) is associated with cardiovascular risk, therefore pharmacologically lowering Lp(a) should automatically reduce events.
Human biology is rarely that cooperative.
A biomarker can be causally related to disease while the degree, timing or method of intervention still proves insufficient to change outcomes in a particular trial. Patients in Lp(a)HORIZON already had established cardiovascular disease and were receiving contemporary therapies addressing other risk factors, which may make incremental benefits more difficult to demonstrate.
The full dataset therefore matters enormously.
Researchers will want to know whether patients achieving the greatest Lp(a) reductions performed differently, whether baseline Lp(a) levels influenced outcomes and whether specific cardiovascular endpoints behaved differently from the composite primary endpoint.
Until those data are available, extrapolating the failure across the entire drug class would go beyond the evidence.
How did investors react to the pelacarsen disappointment?
The announcement was issued after the regular United States trading session on September 4, making the first reaction visible primarily in after-hours trading rather than the regular closing price.
Novartis American depositary receipts had finished regular trading at about $159.86, down 1.98% for the session and within a 52-week range of roughly $121.57 to $170.46.
After the pelacarsen announcement, both Novartis and Ionis shares declined in extended trading. Published market reports indicated a roughly 4% decline for Novartis and a larger fall for Ionis, although precise after-hours percentages varied as trading continued.
The larger sensitivity at Ionis is economically logical.
Novartis is a diversified global pharmaceutical company with multiple large commercial franchises and pipeline programmes. Ionis has greater relative exposure to the economics attached to individual antisense programmes and would have received meaningful milestones and royalties if pelacarsen became a major commercial product.
The market response therefore reflects both scientific disappointment and differences in portfolio concentration.
What happens next for pelacarsen and the broader Lp(a) field?
The most important next event is full presentation of Lp(a)HORIZON data.
Topline failure tells investors that the primary endpoint was missed, but it does not reveal whether the study narrowly missed statistical significance, whether any subgroups benefited, what safety looked like over long follow-up or whether treatment effects changed with the depth of Lp(a) reduction.
Novartis has not announced a regulatory filing based on the topline results. Given failure of the primary endpoint, any path forward would require considerably more supporting evidence than the programme would have needed after a clear cardiovascular-outcomes win.
Competing developers will also scrutinise the data closely because trial design assumptions for their own programmes may need to be revisited.
For cardiovascular drug development, that could become the larger legacy of Lp(a)HORIZON.
The trial successfully lowered the molecule pharmaceutical companies have spent years trying to target. What it did not do was demonstrate that this changed the clinical trajectory of the overall study population.
That distinction transforms pelacarsen from a drug setback into a much broader scientific question: how much Lp(a) reduction, in which patients, using which modality and at what stage of cardiovascular disease is required before a biomarker change becomes a measurable reduction in heart attacks and strokes?
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
